Previous 10 | Next 10 |
home / stock / tak / tak articles
Shares of Argenx (NASDAQ: ARGX) rose nearly 4% on Friday after management announced that the FDA approved its subcutaneously administered Vyvgart H...
U.S. stock futures were mixed this morning, with the Nasdaq futures gaining around 0.2% on Tuesday. Shares of NextEra Energy, Inc. (NYSE:NEE) fell ...
Shares of Ovid Therapeutics Inc (NASDAQ:OVID) dipped 65.7% to $1.1285 after Takeda’s Skyline study in Dravet syndrome missed its primary endp...
Monday, Takeda Pharmaceutical Co Ltd (NYSE:TAK) announced topline data from its SKYLINE and SKYWAY Phase 3 studies of Soticlestat (TAK-935). SKYLIN...
Halozyme Therapeutics (NASDAQ: HALO) announced that it has been granted a new patent in the EU that covers the ENHANZE rHuPH20 product, which ...
Blackstone Inc. (NYSE:BX) is reportedly considering selling the Japanese consumer healthcare firm Alinamin Pharmaceutical Co., previously owned by ...
Wednesday, Takeda Pharmaceutical Co Ltd’s (NYSE:TAK) dengue vaccine received World Health Organization’s (WHO) preq...
Monday, Takeda Pharmaceutical Company Limited (NYSE:TAK) and AC Immune SA (NASDAQ:ACIU) announced an exclusive, worldwide ...
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease Ta...
News, Short Squeeze, Breakout and More Instantly...
Takeda Pharmaceutical Company Limited American Depositary Shares Company Name:
TAK Stock Symbol:
NYSE Market:
Takeda Pharmaceutical Company Limited American Depositary Shares Website:
2024-07-04 20:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Takeda (TOKYO:4502/NYSE:TAK) has announced new assignments of directors, determined at the Board of Directors meeting and at the Audit and Supervisory Committee meeting, following the 148th Ordinary Meeting of Shareholders, held in Osaka today. Takeda's Board of Directors has 11 members servi...
LIVTENCITY Is the First and Only Post-Transplant Anti-CMV Treatment Approved in Japan That Targets/Inhibits UL97 Protein Kinase 1 CMV Is One of the Most Common and Serious Post-transplant Infections and Can Lead to Secondary Infections and Serious Consequences, Including Loss of Trans...